|
Positive response to global question about improved erections |
|||||
| Number (%) with outcome |
|||||
|
|
|||||
| Dosing (mg) |
Number of trials |
Sildenafil |
Placebo |
Relative benefit (95% CI) |
NNT (95% CI) |
|
|
|||||
| 25 |
3 |
192/312 (62) |
114/426 (27) |
2.3 (1.9 to 2.8) |
2.8 (2.4 to 3.5) |
| 50 |
5 |
378/511 (74) |
153/607 (25) |
3.0 (2.6 to 3.5) |
2.1 (1.9 to 2.3) |
| 100 |
5 |
415/506 (82) |
153/607 (25) |
3.3 (2.9 to 3.8) |
1.8 (1.6 to 1.9) |
| 200 |
2 |
152/191 (80) |
39/181 (22) |
3.7 (2.8 to 5.0) |
1.7 (1.5 to 2.0) |
| Dose optimised |
5 |
411/517 (79) |
111/524 (21) |
3.8 (3.2 to 4.5) |
1.7 (1.6 to 1.9) |
Moore et al. BMC Urology 2002 2:6 doi:10.1186/1471-2490-2-6 |
|||||